|
While the regulatory landscape around biosimilars is evolving to encourage efficiency and innovation, the commercial landscape is playing catch-up as the biosimilar void persists.
|
 |
|
The Vega acquisition will see Incyte absorb its first-in-class bleeding disorder candidate, VG039.
|
|
|
The transaction is expected to close later this year, subject to regulatory approvals and other customary closing conditions.
|
|
|
NICE has preliminarily recommended D-VRd for NHS use as a first-line treatment for transplant-ineligible multiple myeloma.
|
|
|
Hympavzi is approved for routine prophylaxis to prevent bleeding episodes in US patients six years and above.
|
|
